Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience

Rearrangement in the anaplastic lymphoma kinase (ALK) gene is one of the oncogenic drivers in non-small cell lung cancer (NSCLC) patients. Several ALK inhibitors (ALKis) have been developed and have demonstrated their efficacy, however the best treatment strategy for ALK positive NSCLC patients has...

Descripción completa

Detalles Bibliográficos
Autores principales: De Carlo, Elisa, Del Savio, Maria Chiara, Polesel, Jerry, Da Ros, Valentina, Berto, Eleonora, Santarossa, Sandra, Chimienti, Emanuela, Fratino, Lucia, Bearz, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880608/
https://www.ncbi.nlm.nih.gov/pubmed/29632648
http://dx.doi.org/10.18632/oncotarget.24573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880608/
https://www.ncbi.nlm.nih.gov/pubmed/29632648
http://dx.doi.org/10.18632/oncotarget.24573

Ejemplares similares